Overview

ODM-207 in Patients With Advance Solid Tumours

Status:
Completed
Trial end date:
2019-05-10
Target enrollment:
Participant gender:
Summary
This is a first-in-man study to assess the safety and tolerability and to characterise the pharmacokinetics of ODM-207.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Orion Corporation, Orion Pharma